Patients & Caregivers
Clinical Hold Lifted for Head and Neck Cancer Study
Head and neck cancers begin in the mouth, nose, throat, larynx, sinuses, or salivary glands. Most are squamous cell carcinomas.
Acute Myelogenous Leukemia Treatment Gets Orphan Drug Designation
H3B-8800, was granted orphan drug designation by the FDA for the treatment of patients with acute myeloid leukemia, and chronic myelomonocytic leukemia.
Twin Saves Sister from Rare Cancer with Radical Procedure
Mariann's plexiform fibrohistiocytic sarcoma had taken over most of her back. Her treatment required a donor that was compatible.
Screening for Nasopharyngeal Cancer Using Epstein-Barr virus DNA
Nasopharyngeal cancer has been linked to the Epstein-Barr virus.
Kadmon Granted FDA Orphan Drug Designation for Rare Lung Cancer Treatment
The FDA granted orphan drug designation to tesevatinib for treatment of non-small cell lung cancer with epithelial growth factor receptor-activating mutations.
Erdheim-Chester Disease Treatment Gets FDA Priority Review and Breakthrough Therapy Designation
The FDA accepted a supplemental New Drug Application and granted Priority Review for Zelboraf, a therapy for Erdheim-Chester disease with a BRAF V600 mutation.
FDA Approves First Treatment for Chronic Graft Versus Host Disease
TheFDA has approved Imbruvica (ibrutinib) for treating adults with chronic graft versus host disease (cGVHD) after failure of one or more treatments.
FDA Approves Idhifa (enasidenib) for Subset of AML Patients
The FDA approved Idhifa (enasidenib) for treating patients with relapsed or refractory AML who have mutations in their IDH2 gene.
Shopping to Support Ovarian Cancer Research
This Saturday, proceeds from shopping on QVC will go towards Ovarian Cancer Research Fund Alliance (OCRFA).
Josh Brolin Is Having Fun Helping the Rare Disease Community
Proceeds from the sales will go to St. Jude Children's Research Hospital and the Epidermolysis Bullosa Medical Research Foundation.
<< Prev Page
Next Page >>
STRATEGIC ALLIANCE PARTNERSHIP PROGRAM >
Familial Chylomicronemia Syndrome
MJH ASSOCIATES >
Specialty Pharmacy Times
Terms & Conditions
Copyright © RareDR 2013-2017 Rare Disease Communications. All Rights Reserved.